Global Restless Legs Syndrome Treatment Market: Overview
Restless legs syndrome, also called Willis-Ekbom disease, is a neurological disorder. It triggers an urge in patients to move their legs. Because the syndrome usually occurs during sleep, it is also considered a type of sleep disorder. People suffering from restless legs syndrome often feel an overwhelming desire to rigorously move their legs, the intensity and frequency of which leads to unpleasant pain in their limbs. This also disturbs their sleep patterns, affecting their health adversely. The condition usually aggravates at night.
Higher prevalence of restless legs syndrome is noted in women than in men. RLS can affect people of all ages but is mostly observed in middle-aged and elderly people. The most common symptoms of RLS include uncomfortable itching and pain in the legs that may cause a disruption in the sleep pattern and ultimately affect a patient’s quality of life. Despite its increasing prevalence, the precise cause of RLS is not yet known. Nevertheless, with extensive investigations being conducted in the field, the RLS market is expected to gain momentum in the near future. As of now, experts attribute the increasing incidence of the disease to genetic factors and instabilities in the dopaminergic balance.
While researchers are yet to discover a specific cure for the disorder, drugs presently available in the market ensure symptomatic treatment. They help in relieving the uneasiness commonly experienced in the disorder. The report studies the prospects for the global restless legs syndrome treatment market in the forthcoming years. The impact of research and development activities on the market’s future outlook is examined in the report in detail. It also presents insights into the various social and economic factors that will influence the market’s growth trajectory between 2016 and 2024.
Global Restless Legs Syndrome Treatment Market: Opportunities and Market Segmentation
Restless legs syndrome causes uneasiness in patients and is also associated with other health issues such as dizziness, headaches, drowsiness, flatulence, dry mouth, and nausea. Patients suffering from restless legs syndrome may also suffer from psychiatric disorders such as depression and a decreased libido. Apart from these, labyrinthitis and other ear disorders, fatigue, irritability, peripheral edema, and nutritional and metabolism disorders indicated by weight gain or increased appetite are also related to the syndrome.
The treatment of restless legs syndrome is still a relatively untapped space. The market is projected to exhibit growth at an increased rate with the development of new drugs, which promise higher efficiency and minimum side effects.
Based on product type, the global restless legs syndrome treatment market can be segmented into Neupro/Leganto, Mirapex/Sifrol/Mirapexin, HORIZANT/Regnite, and Requip. Restless legs syndrome treatment can be segmented into pharmacological and nonpharmacological.
Global Restless Legs Syndrome Treatment Market: Competitive Insights
In order to study the competitive landscape prevailing in the market, the report profiles companies such as GlaxoSmithKline plc., Kyowa Hakko Kirin Co., Boehringer Ingelheim GmbH, Jazz Pharmaceuticals, Inc., and Manhattan Pharmaceuticals. The strengths and weaknesses of the companies are weighed out in the report using SWOT analysis. The analysis also helps the report gauge the threats and opportunities that these companies could face in the near future.
The report offers a complete databank about the global restless legs syndrome treatment market by providing in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information regarding every facet of the market.